JAK1 and melanoma: Interestingly, Zaretsky J.M. et al. [73] showed that, after a first positive response to anti-PD-1 therapy, loss-of-function mutations in Janus kinase 1 (JAK1) and JAK2 appeared in melanomas that exhibited resistance to further treatment.